Alterome Therapeutics, Inc

Alterome Therapeutics, Inc company information, Employees & Contact Information

Alterome Therapeutics, Inc. is a clinical-stage precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. We are a team with expertise in multiple areas of science and operations, dedicated to co-elevating toward our vision to bring life-changing and life-saving therapies to cancer patients. We believe in our journey, in each other, and in our ability to collaboratively develop therapies that will help end cancers. Thus, we seek the best people for our company and provide the resources they need to grow, develop, and accomplish our collective goals. We are moving forward with humility & empathy, fearlessness & resilience, with a sense of inclusion & belonging, open communication and a deep trust. And…we manage to have a lot of fun along the way!

Company Details

Employees
45
Founded
-
Address
13480 Evening Creek Dr N,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, California
Looking for a particular Alterome Therapeutics, Inc employee's phone or email?

Alterome Therapeutics, Inc Questions

News

Alterome Therapeutics Announces New Chief Executive Officer and Chair of the Board of Directors - Business Wire

Alterome Therapeutics Announces New Chief Executive Officer and Chair of the Board of Directors Business Wire

Alterome Therapeutics to Participate in Upcoming Investor Conferences - Business Wire

Alterome Therapeutics to Participate in Upcoming Investor Conferences Business Wire

Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors - Business Wire

Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors Business Wire

Alterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium - Business Wire

Alterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium Business Wire

Alterome Therapeutics Launches With $64M Series A Financing - Business Wire

Alterome Therapeutics Launches With $64M Series A Financing Business Wire

Alterome Therapeutics Presents Pre-Clinical Data Supporting the Development of Lead Program, an AKT1 E17K Inhibitor - Business Wire

Alterome Therapeutics Presents Pre-Clinical Data Supporting the Development of Lead Program, an AKT1 E17K Inhibitor Business Wire

Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies - Business Wire

Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies Business Wire

Alterome Therapeutics Establishes Scientific Advisory Board Comprised of Renowned Oncology Experts - Business Wire

Alterome Therapeutics Establishes Scientific Advisory Board Comprised of Renowned Oncology Experts Business Wire

Alterome Therapeutics Welcomes Andrew S. Chi, M.D., Ph.D., as Chief Medical Officer - Business Wire

Alterome Therapeutics Welcomes Andrew S. Chi, M.D., Ph.D., as Chief Medical Officer Business Wire

Top Alterome Therapeutics, Inc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant